Will CHRYSALIS turn into a butterfly? by Fuereder, T.

Get full text

P16 positivity and regression grade predict survival after neoadjuvant radiotherapy of OSCC by Eder‐Czembirek, C, Sulzbacher, I, Fuereder, T, Selzer, E

Get full text

Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analy... by Minichsdorfer, C., Fuereder, T., Leutner, M., Singer, C.F., Kacerovsky-Strobl, S., Egle, D., Greil, R., Balic, M., Fitzal, F., Pfeiler, G., Frantal, S., Bartsch, R., Gnant, M.

Get full text

447 Extended Analysis for Cancer Treatment (EXACT): Interim analysis of a prospective precision medicine trial by Prager, G, Unseld, M, Waneck, F, Raderer, M, Krainer, M, Fuereder, T, Hejna, M, Staber, P, Scheithauer, W, Schmidinger, M, Thallinger, C, Farkas, L, Reinthaller, A, Polterauer, S, Wrba, F, Muellauer, L, Mader, R, Zielinski, C.C

Get full text

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo by Cejka, D, Kuntner, C, Preusser, M, Fritzer-Szekeres, M, Fueger, B J, Strommer, S, Werzowa, J, Fuereder, T, Wanek, T, Zsebedics, M, Mueller, M, Langer, O, Wacheck, V

Get full text

Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002 by Werzowa, J., Cejka, D., Fuereder, T., Dekrout, B., Thallinger, C., Pehamberger, H., Wacheck, V., Pratscher, B.

Get full text

OS01.5.A Neuron-specific enolase (NSE) and S100 serum levels in patients with active brain metastases from HER2-positive breast cancer treated with trastuzumab-deruxtecan (T-DXd):... by Berghoff, A S, Bartsch, R, Furtner, J, Marhold, M, Bergen, E S, Roider-Schur, S, Starzer, A M, Forstner, H, Rottenmanner, B, Dieckmann, K, Bago-Horvath, Z, Widhalm, G, Ilhan-Mutlu, A, Minichsdorfer, C, Fuereder, T, Singer, C F, Weltermann, A, Haslacher, H, Szekeres, T, Puhr, R, Preusser, M

Get full text

106P Treatment sequencing in PD-L1–positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Exploratory analysis of the phase III KEYNOTE-048 study by Greil, R., Burtness, B., Laban, S., Braña, I., Mesia Nin, R., Fuereder, T., Bratland, Å., Licitra, L.F.L., Rordorf, T., Psyrri, A., Popovtzer, A., Hughes, B., Tahara, M., Lin, J., Gumuscu, B., Lerman, N., Harrington, K.J.

Get full text

Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study by Zeilinger, E. L., Oppenauer, C., Knefel, M., Kantor, V., Schneckenreiter, C., Lubowitzki, S., Krammer, K., Popinger, C., Kitta, A., Kum, L., Adamidis, F., Unseld, M., Masel, E. K., Füreder, T., Zöchbauer-Müller, S., Bartsch, R., Raderer, M., Prager, G., Krauth, M. T., Sperr, W. R., Porpaczy, E., Staber, P. B., Valent, P., Gaiger, A.

Get full text

187P Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2) by Bartsch, R., Berghoff, A.S., Furtner, J., Marhold, M., Starzer, A.M., Forstner, H., Rottenmanner, B., Aretin, B., Bago-Horvath, Z.A., Exner, R., Fuereder, T., Minichsdorfer, C., Hirdler, M., Strasser-Weippl, K., Balic, M., Pfeiler, G., Egle, D., Rumpold, H., Singer, C.F., Preusser, M.

Get full text

23P Enriching for response: Patient selection criteria for A2AR inhibition by EXS-21546 through ex vivo modelling in primary patient material by Vladimer, G., Alt, I., Sehlke, R., Lobley, A., Baumgärtler, C., Stulic, M., Hackner, K., Dzurillova, L., Petru, E., Hadjari, L., Lafleur, J., Singer, J., Krall, N., Šufliarsky, J., Hefler, L., Fuereder, T., Taubert, C., Boudesco, C., Payne, A.

Get full text

Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies by Griffin, Morag, Langemeijer, Saskia, Kulagin, Alexander, Ogawa, Masayo, Yu, Ji, Peffault de Latour, Régis, Latypova, Aigul, Barcellini, Wilma, Barraco, Fiorenza, Beam, Donald, Bettelheim, Peter, Brodsky, Andres, Carnley, Benedict, Cermak, Jaroslav, Chen, Tsai‐Yun, Chew, Lee Ping, Choi, Chul Won, De Guibert, Sophie, Devos, Timothy, Dunaev, Yuri, Dwilewicz‐Trojaczek, Jadwiga, Edahiro, Yoko, Elykomov, Iliya, Engelberger, Maria Ines, Pomponi, Fabrizio, Fuereder, Wolfgang, Fujii, Nobuharu, Fujiwara, Shinichiro, Girault, Stéphane, Gomez Almaguer, David, Gritsaev, Sergey, Hantaweepant, Chattree, Harada, Hiroshi, Höglund, Martin, Husin, Azlan, Ikezoe, Takayuki, Ishiyama, Ken, Jang, Jun Ho, Jo, Deog‐Yeon, Kang, Ka‐Won, Kennedy, James, Kim, Hyo Jung, Kim, Jeong‐A, Kim, Jin Seok, Kimura, Fumihiko, Kosugi, Hiroshi, Kulagin, Alexander, Kulasekararaj, Austin, Lai, Kuan‐Ming, Lee, Gyeong‐Won, Lee, Jae Hoon, Lee, Je‐Hwan, Lee, Jong Wook, Lin, Chien‐Chin, Martynova, Elena, Matsumura, Itaru, Meike, Galina, Menosi Gualandro, Sandra Fátima, Mori, Yasuo, Morita, Kimio, Morselli Ramalho, Fernanda Maria, Muus, Petra, Myasnikov, Alexander, Naito, Kensuke, Ninomiya, Haruhiko, Notaro, Rosario, Okada, Masaya, Okamoto, Shinichiro, Olkhovik, Tatiana, Paquette, Ronald, Park, Joon Seong, Peffault de la Tour, Régis, Piatek, Caroline, Piekarska, Agnieszka, Pospelova, Tatiana, Rojnuckarin, Ponlapat, Rosa Pessoa, Viviani de Lourdes, Rossi, Blanca, Salvino de Araujo, Marco Aurelio, Samuel, Desmond, Shatokhin, Yury, Shelekhova, Tatiana, Sohn, Sang Kyun, Sunami, Kazutaka, Syed Abdul Kadir, Sharifah Shahnaz, Toh, See Guan, Tomita, Akihiro, Torregrosa Diaz, José Miguel, Ueda, Yasutaka, Usuki, Kensuke, Viboonjuntra, Pongtep, Viigimaa, Iige, Volkova, Svetlana, Won, Jong‐Ho, Wong, Lily Lee Lee, Wong, Voon Fei, Yap, Eng Soo, Yeh, Su‐Peng, Yhim, Ho‐Young, Zhuravkov, Andrey

Get full text

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo by CEJKA, D, KUNTNER, C, MUELLER, M, LANGER, O, WACHECK, V, PREUSSER, M, FRITZER-SZEKERES, M, FUEGER, B. J, STROMMER, S, WERZOWA, J, FUEREDER, T, WANEK, T, ZSEBEDICS, M

Get full text

278 mTOR Inhibition for patients with hepatocellular carcinoma undergoing liver transplantation: Is there a rationale? by Sieghart, W., Fuereder, T., Schmid, K., Cejka, D., Wrba, E., Wang, X., Gruber, D., Rasoul-Rockenschaub, S., Peck-Radosavljevic, M., Wacheck, V.

Get full text

69 POSTER Therapeutic effect of everolimus (RAD001) in combination with antiangiongenic chemotherapy for gastric cancer in vivo by Cejka, D., Preusser, M., Sieghart, W., Strommer, S., Werzowa, J., Fuereder, T., Wacheck, V.

Get full text

Wenn sich Übergewicht zum klinischen Vorteil wandelt: Assoziation zwischen Body-Mass-Index und Therapieansprechen von Checkpointinhibitoren in einer Kohorte gynäkoonkologischer Pat... by Bartl, T, Onoprienko, A, Reinthaller, A, Füreder, T, Aust, S, Hofstetter, G, Grimm, C

Get full text

Cancer of unknown primary—state of the art by Fuereder, Thorsten

Get full text

Nasopharyngeal carcinoma: Essential news regarding current guidelines by Fuereder, Thorsten

Get full text

Essential news of current guidelines: head and neck squamous cell carcinoma by Fuereder, Thorsten

Get full text

ASCO 2021 highlights head and neck cancer: nasopharyngeal carcinoma by Fuereder, Thorsten

Get full text